The platform was sitting on a large, valuable clinical dataset riddled with the most sensitive categories of protected health information, including substance-use-disorder data governed by 42 CFR Part 2, which is far stricter than ordinary HIPAA PHI.
That sensitivity made the data effectively untouchable: it could not be shared, analyzed with outside tools, or monetized without enormous legal exposure. A real revenue asset was trapped behind compliance risk.
OutcomeCatalyst built a de-identification layer for the platform's clinical dataset that strips and protects both standard HIPAA PHI and the stricter substance-use-disorder data governed by 42 CFR Part 2, all inside a compliant environment. The result is clean, structured data the business can analyze, package, and sell without the prior legal exposure.
Data that was previously impossible to touch became a monetizable data asset, a new revenue stream created out of what had been pure liability.
De-identification covers both standard HIPAA PHI and the stricter substance-use-disorder (Part 2) categories inside a compliant environment.
Records that could not be shared, analyzed, or monetized without major legal exposure became clean, structured, packageable data.
- How a Federal Staffing Firm Cut Bid Pricing Error 42% With AITopsail · Healthcare & Life Sciences
- How Relay Found $100K a Month in Missed BillingSynopsis · Construction & Engineering
- How a Finance Team Cut Month-End Close 10 Days to 1QuantFi · Financial Services
- How Element5 Put Agentic AI Inside 21 of 30 Top ProvidersIdeas2IT Technologies · Healthcare & Life Sciences